Radiosensitization of brain metastasis by targeting c-MET

Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced apoptosis specifically in tumor cells. However, with approximately half of all known tumor lines being resistant to TRAIL, the identification of TRAIL sensitizers and their mechanism of action become critical to broadly use TRAIL as a therapeutic agent. In this study, we explored whether c-Met protein contributes to TRAIL s...

Targeting c-Met in melanoma

Selective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization

Successful treatment of brain tumors such as glioblastoma multiforme (GBM) is limited in large part by the cumulative dose of Radiation Therapy (RT) that can be safely given and the blood-brain barrier (BBB), which limits the delivery of systemic anticancer agents into tumor tissue. Consequently, the overall prognosis remains grim. Herein, we report our pilot studies in cell culture experiments...

MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression

Gastric cancer (GC) remains one of the most common types of malignant cancer, and the molecular mechanism underlying its metastasis is still largely unclear. MicroRNAs have emerged as important regulators of metastasis because of their ability to act on multiple signaling pathways. In our study, we found that miR-144 is significantly downregulated in both highly metastatic GC cell lines and tis...

Targeting the HGF/c-Met axis: state of play.

In a recent issue ofMolecular Cancer Therapeutics, Burgess and colleagues (1) give a detailed biochemical and functional characterization of AMG 102, a fully humanized monoclonal antibody to hepatocyte growth factor (HGF). HGF, or scatter factor, is the only known high-affinity ligand for the c-Met receptor tyrosine kinase (2). Upon ligand binding, c-Met undergoes dimerization, autophosphorylat...